According to Reuters, EnteroMedics Inc stock shares have risen by as much as 74 percent after the company received FDA approval for a device aimed at combatting obesity. The Maestro Rechargeable System targets the nerve pathway between the brain and the stomach in order to control hunger and feelings of fullness. Once implanted into the abdomen, the device sends electrical pulses that interfere with the activity of the vagus nerve which tells the brain when the stomach is empty. Clinical trials found that patients with the device lost 8.5 percent more weight than those without it. However, despite the approval, the product will not be brought to market until a five-year study is completed to gather more information on the product’s safety and side effects.